Clinical trials
Active, not recruiting Phase 1 Prostatic Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
62 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 8 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 8 |
| 2025 | 8 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 62 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 5 |
| Jonsson Comprehensive Cancer Center | 4 |
| City of Hope Medical Center | 3 |
| Eli Lilly and Company | 3 |
| Dana-Farber Cancer Institute | 2 |
| M.D. Anderson Cancer Center | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| Novartis Pharmaceuticals | 2 |
| Shanghai Changzheng Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 62 |
| Ovarian Neoplasms | 12 |
| Triple Negative Breast Neoplasms | 9 |
| Breast Neoplasms | 8 |
| Endometrial Neoplasms | 8 |
| Melanoma | 8 |
| Neoplasm Metastasis | 8 |
| Uterine Cervical Neoplasms | 7 |
| Carcinoma, Renal Cell | 6 |
| Urinary Bladder Neoplasms | 6 |
Trials
Showing 1 to 25 of 62. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.